[EN] TREATMENT OR PREVENTION OF LEUKAEMIA<br/>[FR] TRAITEMENT OU PRÉVENTION DE LA LEUCÉMIE
申请人:VESTLANDETS INNOVASJONSSELSKAP AS
公开号:WO2021074614A1
公开(公告)日:2021-04-22
The present invention provides compounds for use in the treatment or prevention of leukaemia which are based on a 2-amino-[1,1']-bipbenyl or corresponding carbazole scaffold, in particular, it provides the following compounds of formula (I), their stereoisomers, and their pharmaceutically acceptable salts for use in such treatment: (I) (I) wherein: Y is selected from C=0 and -CR9 (in which R9 is H, -OH or -O-alkyl, (e.g, -O-C1-6 alkyl)); Z is selected from C=0 and -CR10 (in which R10 is H, -OH, -O-alkyl, (e.g, -O-C1-6 alkyl) or -O-C(O)RA wherein RA is H or alkyl (e.g. C1-6 alkyl)); R1 is -NO2 or -NR11R12 (wherein R11 and R12 are both H, or R11 is H and R12 is a group of the formula -C(O)RA in which RA is H or alkyl (e.g. C1-6 alkyl)); each of R2, R4, and R6 to R8 are independently selected from H, alkyl (e.g. C1-6 alkyl), -O-alkyl (e.g. -O-C1-6 alkyl), and halogen; R3 and R5 are independently selected from H, -O-alkyl (e.g. -O-C1-6 alkyl), and halogen; or R1 and R8 together form a group NR13 (in which R13 is H, alkyl (e.g. C1-6 alkyl), or a group of the formula -C(O)RA in which RA is H or alkyl (e.g. G1-6 alkyl)); and represents an optional bond between two adjacent carbon atoms in the ring; with the proviso that when Y and Z are both C=O, and R1 and R8 together form a group NR13, at least one of R2 and R3 is other than H or -CH3. Such compounds find particular use in the treatment or prevention of chronic myeloid leukaemia (GML), acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL) or t-ALL (T-cell acute lymphoblastic leukaemia).
本发明提供了用于治疗或预防白血病的化合物,这些化合物基于2-氨基-[1,1']-联苯或相应的咔唑骨架,具体而言,它提供了以下式(I)的化合物,它们的立体异构体和其在此类治疗中可接受的盐:(I)其中:Y选自C=0和-CR9(其中R9为H,-OH或-O-烷基(例如,-O-C1-6烷基));Z选自C=0和-CR10(其中R10为H,-OH,-O-烷基(例如,-O-C1-6烷基)或-O-C(O)RA,其中RA为H或烷基(例如,C1-6烷基));R1为-NO2或-NR11R12(其中R11和R12都为H,或R11为H且R12为式-C(O)RA的基团,其中RA为H或烷基(例如,C1-6烷基));R2、R4和R6至R8中的每一个独立选择自H、烷基(例如,C1-6烷基)、-O-烷基(例如,-O-C1-6烷基)和卤素;R3和R5独立选择自H、-O-烷基(例如,-O-C1-6烷基)和卤素;或R1和R8一起形成一个基团NR13(其中R13为H、烷基(例如,C1-6烷基)或式-C(O)RA的基团,其中RA为H或烷基(例如,C1-6烷基));并表示环中两个相邻碳原子之间的可选键;但是当Y和Z都是C=O时,并且R1和R8一起形成一个基团NR13时,R2和R3中至少有一个不是H或-CH3。这些化合物在治疗或预防慢性髓性白血病(GML)、急性髓性白血病(AML)、急性淋巴细胞白血病(ALL)或T-ALL(T细胞急性淋巴细胞白血病)中找到特定用途。